Development of a stable oral liquid dosage form of spironolactone
- 1 August 1992
- journal article
- Published by Hindawi Limited in Journal of Clinical Pharmacy & Therapeutics
- Vol. 17 (4) , 245-248
- https://doi.org/10.1111/j.1365-2710.1992.tb01300.x
Abstract
A clear, stable, oral liquid dosage form of spironolactone has been developed. Solubility profiles of spironolactone were obtained in several co-solvent blends. Using this data, a co-solvent blend containing polyethylene glycol 400 (30% v/v), propylene glycol (10% v/v), glycerin (10% v/v) and ethyl alcohol (10% v/v) was used to solubilize spironolactone at a concentration of 2 mg/ml. The final formulation contained sweetening agents (sucrose, saccharin sodium), flavours (cherry, sweet), a desensitizing agent (menthol), a dye (FD&C Red #40) and a preservative (benzoic acid) to incorporate the desired organoleptic and preservative properties. A phosphate buffer was used to maintain a pH value of 4.5 (pH of maximum stability as reported earlier) to minimize hydrolysis. The final dosage form was stable for at least 93 days at 40°C (loss of potency less than 4%). According to FDA guidelines, a tentative expiry date of 2 years at 25°C is justifiable.Keywords
This publication has 4 references indexed in Scilit:
- Preformulation Studies of Spironolactone: Effect of pH, Two Buffer Species, Ionic Strength, and Temperature on StabilityJournal of Pharmaceutical Sciences, 1991
- Quantitation of spironolactone in the presence of canremone using high-performance liquid chromatographyDrug Development and Industrial Pharmacy, 1991
- Mineral excretion in premature infants receiving various diuretic therapiesThe Journal of Pediatrics, 1988
- Diuretic therapy in infants and childrenThe Journal of Pediatrics, 1976